目的检测哮喘小鼠与对照小鼠肺组织中Th1、Th2、Th17及Foxp3+Treg细胞占CD4+T细胞百分比,探讨哮喘小鼠中Foxp3+Treg/Th17比值变化及其在哮喘中的意义。方法将6周清洁级Balb/c小鼠随机分为对照组(control)和哮喘组(OVA),哮喘组给予OVA致...目的检测哮喘小鼠与对照小鼠肺组织中Th1、Th2、Th17及Foxp3+Treg细胞占CD4+T细胞百分比,探讨哮喘小鼠中Foxp3+Treg/Th17比值变化及其在哮喘中的意义。方法将6周清洁级Balb/c小鼠随机分为对照组(control)和哮喘组(OVA),哮喘组给予OVA致敏和激发,建立哮喘小鼠模型,对照组用PBS代替OVA。最后1次激发后24 h内检测支气管肺泡灌洗液(BALF)中细胞总数及细胞分类计数;HE染色制作肺组织病理切片,光镜下观察病理变化;小鼠肺功能仪检测小鼠气道高反应性;流式细胞术检测小鼠肺组织中Th1、Th2、Th17、Foxp3+Treg细胞占CD4+T细胞百分比。结果哮喘组BALF细胞总数、淋巴细胞、嗜酸性粒细胞及中性粒细胞比例显著高于对照组,肺部炎症反应与气道高反应显著高于对照组。哮喘组小鼠肺组织中Th2、Th17细胞百分比明显高于对照组[分别为(0.83±0.08)%vs(0.50±0.03)%;(1.74±0.17)%vs(1.07±0.07)%,P<0.01];而Th1、Foxp3+Treg细胞百分比显著低于对照组[分别为(1.39±0.14)%vs(2.56±0.18)%;(4.87±0.35)%vs(7.67±0.44)%,P<0.001];哮喘组Th1/Th2及Foxp3+Treg/Th17明显低于对照组(分别为1.66±0.17 vs 5.19±0.56;3.02±0.49 vs 7.38±0.71,P<0.001)。结论除Th1/Th2失衡外,Foxp3+Treg/Th17失衡在哮喘发病中亦有重要作用。展开更多
Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission wer...Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission were divided into two combination group(control group, the combination of budesonide and terbutaline) and A. membranaceus group(treatment group, the combination of budesonide, terbutaline and A. membranaceus). The therapeutic results were compared between two groups after 3-month therapy.Porcine peripheral blood mononuclear cells(PBMCs) were isolated from venous blood by using density gradient centrifugation on percoll. The levels of Fox P3, EGF-β, IL-17 and IL-23 from PBMCs and serum Ig E were measured. The relative percentage of Treg/Th17 cells was determined using flow cytometry. The main components of A. membranaceus were calycosin-7-O-glucoside, isoquercitrin, ononin, calycosin, quercetin, genistein, kaempferol, isorhamnetin and formononetin, all of which may contribute to asthma therapy. Lung function was significantly improved in the treatment group when compared with a control group(P < 0.05). The efficacy in preventing the occurrence of childhood asthma was higher in the treatment group than the control group(P < 0.05).The levels of Ig E, IL-17 and IL-23 were reduced significantly in the treatment group when compared with the control group, while the levels of FoxP3 and TGF-β were increased in the treatment group when compared with the control group(P < 0.05). A. membranaceus increased the percentage of Treg cells and reduced the percentage of Th17 cells. A. membranaceus is potential natural product for improving the therapeutic efficacy of combination therapy of budesonide and terbutaline for the children with asthma remission by modulating the balance of Treg/Th17 cells.展开更多
文摘目的检测哮喘小鼠与对照小鼠肺组织中Th1、Th2、Th17及Foxp3+Treg细胞占CD4+T细胞百分比,探讨哮喘小鼠中Foxp3+Treg/Th17比值变化及其在哮喘中的意义。方法将6周清洁级Balb/c小鼠随机分为对照组(control)和哮喘组(OVA),哮喘组给予OVA致敏和激发,建立哮喘小鼠模型,对照组用PBS代替OVA。最后1次激发后24 h内检测支气管肺泡灌洗液(BALF)中细胞总数及细胞分类计数;HE染色制作肺组织病理切片,光镜下观察病理变化;小鼠肺功能仪检测小鼠气道高反应性;流式细胞术检测小鼠肺组织中Th1、Th2、Th17、Foxp3+Treg细胞占CD4+T细胞百分比。结果哮喘组BALF细胞总数、淋巴细胞、嗜酸性粒细胞及中性粒细胞比例显著高于对照组,肺部炎症反应与气道高反应显著高于对照组。哮喘组小鼠肺组织中Th2、Th17细胞百分比明显高于对照组[分别为(0.83±0.08)%vs(0.50±0.03)%;(1.74±0.17)%vs(1.07±0.07)%,P<0.01];而Th1、Foxp3+Treg细胞百分比显著低于对照组[分别为(1.39±0.14)%vs(2.56±0.18)%;(4.87±0.35)%vs(7.67±0.44)%,P<0.001];哮喘组Th1/Th2及Foxp3+Treg/Th17明显低于对照组(分别为1.66±0.17 vs 5.19±0.56;3.02±0.49 vs 7.38±0.71,P<0.001)。结论除Th1/Th2失衡外,Foxp3+Treg/Th17失衡在哮喘发病中亦有重要作用。
文摘Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission were divided into two combination group(control group, the combination of budesonide and terbutaline) and A. membranaceus group(treatment group, the combination of budesonide, terbutaline and A. membranaceus). The therapeutic results were compared between two groups after 3-month therapy.Porcine peripheral blood mononuclear cells(PBMCs) were isolated from venous blood by using density gradient centrifugation on percoll. The levels of Fox P3, EGF-β, IL-17 and IL-23 from PBMCs and serum Ig E were measured. The relative percentage of Treg/Th17 cells was determined using flow cytometry. The main components of A. membranaceus were calycosin-7-O-glucoside, isoquercitrin, ononin, calycosin, quercetin, genistein, kaempferol, isorhamnetin and formononetin, all of which may contribute to asthma therapy. Lung function was significantly improved in the treatment group when compared with a control group(P < 0.05). The efficacy in preventing the occurrence of childhood asthma was higher in the treatment group than the control group(P < 0.05).The levels of Ig E, IL-17 and IL-23 were reduced significantly in the treatment group when compared with the control group, while the levels of FoxP3 and TGF-β were increased in the treatment group when compared with the control group(P < 0.05). A. membranaceus increased the percentage of Treg cells and reduced the percentage of Th17 cells. A. membranaceus is potential natural product for improving the therapeutic efficacy of combination therapy of budesonide and terbutaline for the children with asthma remission by modulating the balance of Treg/Th17 cells.
